SINGAPORE (Sept 10): Biolidics has entered into an agreement with the Genome Institute of Singapore (GIS) to collaborate and develop a new and innovative liquid biopsy test in the field of circulating tumour cells (CTCs) for the assessment of minimal residual disease (MRD) and predicting the risk o...

SINGAPORE (Sept 9): Biolidics, the medical technology company, is collaborating with Hangzhou Normal University to undertake clinical investigations to validate the clinical utility of CTCs as a biomarker in late stage lung cancer. In addition, the group’s liquid biopsy solutions will be used as ...

SINGAPORE (July 29): Clearbridge Health is raising $11.34 million from a share placement exercise to accelerate its growth plans in Asia’s healthcare market. Under the terms of the share placement agreement, Clearbridge, will issue some 80.5 million new ordinary shares at 14.1 cents each. This is...

CATALIST-LISTED medical technology firm Biolidics on Tuesday morning requested an immediate trading halt, pending a revised press statement with clarifications on the reimbursement for cancer laboratory-developed tests (LDTs) in China.

THE following companies saw new developments that may affect trading of their shares on Tuesday:

SINGAPORE (June 25): Medical technology company Biolidics has entered into a partnership with Zhongshan TopGene Medical Laboratory Co to develop and commercialise laboratory-developed tests (LDTs) in the field of circulating tumour cells (CTCs) using Biolidics' ClearCell FX1 System and CTChip FR1 b...

SINGAPORE (Apr 1): Phillip Securities is initiating coverage of Clearbridge Health (CBH) with a “buy”. Phillip likes CBH’s business strategy of acquiring asset-light and fast-growing healthcare segments. After the acquisition, the group will then grow the businesses through expansion in capac...

SINGAPORE (Apr 1): Phillip Securities is initiating coverage of Clearbridge Health (CBH) with a “buy”. Phillip likes CBH’s business strategy of acquiring asset-light and fast-growing healthcare segments. After the acquisition, the group will then grow the businesses through expansion in capac...

SINGAPORE (Mar 27): CGS-CIMB is starting coverage of biotech firm Biolidics at “add” given it is the developer of game-changing liquid biopsy technology for detecting cancer. CGS-CIMB says liquid biopsy offers several advantages over tissue biopsy, including greater availability, higher quality...

SINGAPORE (Feb 20): Biolidics Limited has established a strategic partnership with Sysmex Corporation, a Tokyo Stock Exchange-listed supplier of hematology instruments, to collaborate on the development of laboratory assays in the field of circulating tumour cells. See: Biolidics selling 27.5 mil n...